BrightSpring, Centene stand out as healthcare's most persistent Strong Buys
at seekingalpha.com (Thu, 12-Nov 7:38 AM)
Xencor spotlights 400 mcg/kg XmAb819 dose after 45.5% confirmed response rate in Phase 1 kidney cancer cohort
Market Chameleon (Mon, 26-Oct 10:25 AM)